80 related articles for article (PubMed ID: 10206310)
21. An early- and late-stage convolution model for disease natural history.
Pinsky PF
Biometrics; 2004 Mar; 60(1):191-8. PubMed ID: 15032789
[TBL] [Abstract][Full Text] [Related]
22. [Clinical analysis and long-term follow up study of asymptomatic nasopharyngeal carcinoma patients].
Ji MF; Guo YQ; Zheng SA; Liang JS; Wang DK; Ou XT
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):53-6. PubMed ID: 12778770
[TBL] [Abstract][Full Text] [Related]
23. Polymerase chain reaction study of Epstein-Barr virus in high risk group of nasopharyngeal carcinoma: a preliminary report.
Luxamechanporn T; Neimhom S; Kunachak S; Kulapaditharom B
J Med Assoc Thai; 1999 Jun; 82(6):593-7. PubMed ID: 10443082
[TBL] [Abstract][Full Text] [Related]
24. Distribution of Epstein-Barr virus genotypes in throat washings, sera, peripheral blood lymphocytes and in EBV positive tumor biopsies from Slovenian patients with nasopharyngeal carcinoma.
Klemenc P; Marin J; Soba E; Gale N; Koren S; Strojan P
J Med Virol; 2006 Aug; 78(8):1083-90. PubMed ID: 16789009
[TBL] [Abstract][Full Text] [Related]
25. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
Barbiere JM; Lyratzopoulos G
Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of nasopharyngeal carcinoma in Malaysia and Hong Kong.
Yu MC; Ho JH; Henderson BE; Armstrong RW
Natl Cancer Inst Monogr; 1985 Dec; 69():203-7. PubMed ID: 3834333
[TBL] [Abstract][Full Text] [Related]
28. Screening for otitis media with effusion to measure its prevalence in Chinese children in Hong Kong.
Tong MC; Yue V; Ku PK; Lo PS; van Hasselt CA
Ear Nose Throat J; 2000 Aug; 79(8):626-30. PubMed ID: 10969473
[TBL] [Abstract][Full Text] [Related]
29. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
30. Estimating sample size for a randomized clinical trial of lung cancer screening.
Obuchowski NA
Contemp Clin Trials; 2008 Jul; 29(4):466-77. PubMed ID: 18088564
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
32. Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening.
Weedon-Fekjaer H; Tretli S; Aalen OO
Stat Methods Med Res; 2010 Oct; 19(5):507-27. PubMed ID: 20356856
[TBL] [Abstract][Full Text] [Related]
33. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM).
Kuo HS; Chang HJ; Chou P; Teng L; Chen TH
Int J Epidemiol; 1999 Apr; 28(2):233-40. PubMed ID: 10342684
[TBL] [Abstract][Full Text] [Related]
34. Multi-state Markov models in cancer screening evaluation: a brief review and case study.
Uhry Z; Hédelin G; Colonna M; Asselain B; Arveux P; Rogel A; Exbrayat C; Guldenfels C; Courtial I; Soler-Michel P; Molinié F; Eilstein D; Duffy SW
Stat Methods Med Res; 2010 Oct; 19(5):463-86. PubMed ID: 20231370
[TBL] [Abstract][Full Text] [Related]
35. Changing patterns of nasopharyngeal carcinoma incidence in Hong Kong: a 30-year analysis and future projections.
Wang X; Sun H; Li L; Gan Z; Wu X; Du J
BMC Cancer; 2023 Aug; 23(1):761. PubMed ID: 37587425
[TBL] [Abstract][Full Text] [Related]
36. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase.
Duffy SW; Chen HH; Tabar L; Day NE
Stat Med; 1995 Jul; 14(14):1531-43. PubMed ID: 7481190
[TBL] [Abstract][Full Text] [Related]
37. Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening.
Ng WT; Choi CW; Lee MC; Chan SH; Yau TK; Lee AW
Fam Cancer; 2009; 8(2):103-8. PubMed ID: 18726711
[TBL] [Abstract][Full Text] [Related]
38. Incidence rate trends of histological subtypes of nasopharyngeal carcinoma in Hong Kong.
Tse LA; Yu IT; Mang OW; Wong SL
Br J Cancer; 2006 Nov; 95(9):1269-73. PubMed ID: 17031401
[TBL] [Abstract][Full Text] [Related]
39. Multiple malignant neoplasms in patients with nasopharyngeal carcinoma.
Sham JS; Wei WI; Tai PT; Choy D
Oncology; 1990; 47(6):471-4. PubMed ID: 2243665
[TBL] [Abstract][Full Text] [Related]
40. [Geopathology of malignant nasopharyngeal neoplasms].
Strelka J; Barta T
Cesk Otolaryngol; 1974 Jul; 23(3):165-9. PubMed ID: 4847093
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
